New Biomarker Could Predict Lung Cancer Gene Therapy Response
Adults with non-small cell lung cancer may one day have a test to help identify who responds to REQORSA, though this is early research.
Updated on Nov. 4, 2026 in Health

Genprex announced research identifying TROP2 as a potential predictive biomarker for its REQORSA gene therapy in non-small cell lung cancer, with findings to be presented at the 2026 EORTC-NCI-AACR Symposium in Barcelona, Spain. The research is relevant to lung cancer patients and clinical investigators evaluating which patients may respond to this experimental therapy.
Why it matters
A biomarker that predicts which lung cancer patients are more likely to respond to a targeted therapy could help clinical trials select more applicable patients and could sharpen treatment decisions as new options are studied. The work is at an early stage, so its value depends on confirmation in further studies.
The findings combine preclinical models of non-small cell lung cancer with analysis of pretreatment tumor biopsies from patients in a REQORSA clinical trial. Laboratory studies at MD Anderson reported TUSC2 uptake in tumor cells at 10 to 33 times the uptake in normal cells, but the source does not report patient numbers or effect sizes for the biopsy analysis.
The players
Genprex, Inc.
An Austin, Texas company developing REQORSA, a TUSC2 gene therapy being studied for non-small cell and small cell lung cancer.
MD Anderson
The Texas cancer center where laboratory studies showed TUSC2 uptake in tumor cells was 10 to 33 times the uptake in normal cells.
The details
REQORSA is a plasmid carrying the TUSC2 gene, packaged in non-viral lipid-based nanoparticles and injected intravenously. It is designed to deliver the gene to negatively charged cancer cells while minimizing uptake by normal tissue. In the research, low TROP2 expression was consistently associated with resistance to REQORSA across multiple preclinical models, which is why TROP2 is being studied as a predictor of response.
Timeline
November 4, 2026: Genprex announced the TROP2 biomarker research.
November 18-20, 2026: The 2026 EORTC-NCI-AACR Symposium is held in Barcelona, Spain.
November 18, 2026: A featured poster session runs from 12:00 to 6:00 p.m. CET.
Health Landscape
REQORSA's lung cancer programs hold FDA Fast Track Designation, and its small cell lung cancer program also holds Orphan Drug designation. Identifying a biomarker like TROP2 would fit a broader push to match experimental therapies to patients most likely to respond, rather than enrolling trial participants without that information.
For people with non-small cell lung cancer, this research is an early signal that a tumor's TROP2 level may someday help predict whether certain targeted therapies are worth trying. Anyone with lung cancer who wants to know whether a trial is appropriate for them should discuss it with their oncologist.
The takeaway
A tumor marker that predicts response could make lung cancer trials more precise and treatment choices more informed. Patients considering clinical trials should ask their oncologist whether biomarker testing is available and relevant to their case.
What happens next
Genprex plans to post the EORTC-NCI-AACR 2026 poster on its website following the November 18, 2026 presentation, subject to conference disclosure requirements.
Further reading
For related coverage, see Cancer in Austin.





